EcoDrugPlus

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSSAG00000064529
Gene Symbol: HTR3B
2 Cross references
170 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSSAG00000016363
Gene Symbol: HTR3B
2 Cross references
168 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSSAG00000042720
Gene Symbol: LOC106604930
4 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 4-Like

Ensembl ID : ENSSSAG00000004627
Gene Symbol: LOC106611927
4 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSSAG00000060915
Gene Symbol: HTR5A
5 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSSAG00000098816
Gene Symbol: LOC106579046
4 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSSAG00000085294
Gene Symbol: LOC106578832
4 Cross references
190 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSSAG00000113948
Gene Symbol: LOC106589226
4 Cross references
147 Possible Orthologues:

60s Acidic Ribosomal Protein P1

Ensembl ID : ENSSSAG00000063156
Gene Symbol: LOC106588994
5 Cross references
363 Possible Orthologues:

60s Ribosomal Protein L13a

Ensembl ID : ENSSSAG00000003176
Gene Symbol: LOC106610677
4 Cross references
362 Possible Orthologues:

60s Ribosomal Protein L14

Ensembl ID : ENSSSAG00000042831
Gene Symbol: LOC106570647
3 Cross references
303 Possible Orthologues:

60s Ribosomal Protein L18

Ensembl ID : ENSSSAG00000002140
Gene Symbol: LOC106577306
4 Cross references
374 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).